BR112013022217A2 - composição farmacêutica, método de tratamento preventivo de uma síndroma hemorrágica em um paciente com hemofilia a ou b e método de tratamento de um acidente hemorrágico em um paciente com hemofilia a ou b - Google Patents

composição farmacêutica, método de tratamento preventivo de uma síndroma hemorrágica em um paciente com hemofilia a ou b e método de tratamento de um acidente hemorrágico em um paciente com hemofilia a ou b

Info

Publication number
BR112013022217A2
BR112013022217A2 BR112013022217A BR112013022217A BR112013022217A2 BR 112013022217 A2 BR112013022217 A2 BR 112013022217A2 BR 112013022217 A BR112013022217 A BR 112013022217A BR 112013022217 A BR112013022217 A BR 112013022217A BR 112013022217 A2 BR112013022217 A2 BR 112013022217A2
Authority
BR
Brazil
Prior art keywords
patient
haemophilia
hemorrhagic
pharmaceutical composition
accident
Prior art date
Application number
BR112013022217A
Other languages
English (en)
Other versions
BR112013022217A8 (pt
Inventor
Thomas Aline
Polack Benoit
Original Assignee
Centre Nat Rech Scient
Univ Joseph Fourier (Grenoble 1)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Joseph Fourier (Grenoble 1) filed Critical Centre Nat Rech Scient
Publication of BR112013022217A2 publication Critical patent/BR112013022217A2/pt
Publication of BR112013022217A8 publication Critical patent/BR112013022217A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composição farmacêutica, método de tratamento preventivo de uma síndrome hemorrágica em um paciente com hemofilia a ou b e método de tratamento de um acidente hemorrágico em um paciente com hemofilia a ou b a presente invenção refere-se a uma composição farmacêutica compreendendo um fatox xa (modificado) (gdxa), referido gdxa modificado sendo não trombogênico, capaz de se ligar a tfpi, mas não capaz de se ligar a fosfolipídios, para prevenir ou tratar um acidente hemorrágico em um paciente com hemofilia a ou b ou sem inibidor.
BR112013022217A 2011-03-01 2012-02-29 composição farmacêutica, método de tratamento preventivo de uma síndrome hemorrágica em um paciente com hemofilia a ou b e método de tratamento de um acidente hemorrágico em um paciente com hemofilia a ou b BR112013022217A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1151637A FR2972114B1 (fr) 2011-03-01 2011-03-01 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
PCT/FR2012/050425 WO2012117203A1 (fr) 2011-03-01 2012-02-29 Facteur xa depourvu de domaine gla pour le traitement des hemophilies a ou b avec ou sans inhibiteur

Publications (2)

Publication Number Publication Date
BR112013022217A2 true BR112013022217A2 (pt) 2017-06-06
BR112013022217A8 BR112013022217A8 (pt) 2018-01-02

Family

ID=44515164

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013022217A BR112013022217A8 (pt) 2011-03-01 2012-02-29 composição farmacêutica, método de tratamento preventivo de uma síndrome hemorrágica em um paciente com hemofilia a ou b e método de tratamento de um acidente hemorrágico em um paciente com hemofilia a ou b

Country Status (10)

Country Link
US (1) US9493761B2 (pt)
EP (1) EP2680876B1 (pt)
JP (1) JP2014508159A (pt)
KR (1) KR20140033010A (pt)
CN (1) CN103429255A (pt)
AU (1) AU2012223048A1 (pt)
BR (1) BR112013022217A8 (pt)
CA (1) CA2828789C (pt)
FR (1) FR2972114B1 (pt)
WO (1) WO2012117203A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049804A1 (en) 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
SG11201505627RA (en) * 2013-01-24 2015-08-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
EP2950813B1 (en) 2013-01-31 2019-09-04 Pfizer Inc Compositions and methods for counteracting factor xa inhibition
CN104211802B (zh) * 2013-05-29 2018-07-27 成都渊源生物科技有限公司 人凝血因子轻链蛋白及其应用
FR3007410B1 (fr) * 2013-06-21 2016-05-27 Lab Francais Du Fractionnement Facteur x depourvu de domaine gla
CN105579468A (zh) 2013-09-24 2016-05-11 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
FR3064917A1 (fr) * 2017-04-07 2018-10-12 Universite Grenoble Alpes Facteur x mute
FR3088542B1 (fr) 2018-11-21 2021-03-19 Waterdiam France Sas Composition cicatrisante comprenant une eau électrolysée

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807411B2 (en) 2006-05-23 2010-10-05 The Scripps Research Institute Genetically encoded fluorescent coumarin amino acids
HUE052423T2 (hu) * 2007-09-28 2021-04-28 Alexion Pharma Inc Az XA faktor inhibitorok antidótumai és ezek alkalmazási módszerei
MX2011004907A (es) * 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.

Also Published As

Publication number Publication date
US9493761B2 (en) 2016-11-15
CN103429255A (zh) 2013-12-04
FR2972114B1 (fr) 2013-03-15
EP2680876B1 (fr) 2015-11-04
CA2828789C (fr) 2020-03-31
CA2828789A1 (fr) 2012-09-07
US20140050716A1 (en) 2014-02-20
WO2012117203A1 (fr) 2012-09-07
KR20140033010A (ko) 2014-03-17
JP2014508159A (ja) 2014-04-03
FR2972114A1 (fr) 2012-09-07
AU2012223048A1 (en) 2013-10-03
BR112013022217A8 (pt) 2018-01-02
EP2680876A1 (fr) 2014-01-08

Similar Documents

Publication Publication Date Title
BR112013022217A2 (pt) composição farmacêutica, método de tratamento preventivo de uma síndroma hemorrágica em um paciente com hemofilia a ou b e método de tratamento de um acidente hemorrágico em um paciente com hemofilia a ou b
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112014033102A2 (pt) produto para uso no tratamento profilático ou terapêutico de uma emoção negativa ou comportamento introvertido
EA201792479A3 (ru) Комбинация оксиданта и фотоактиватора для заживления ран
NZ602219A (en) Methods and compositions for treating degos’ disease
EA201690904A1 (ru) Антибактериальная композиция для ротовой полости
BR112012016633A2 (pt) composição farmacêutica em pó seco e método de tratamento de ferida.
ECSP12011962A (es) Tratamientos para trastornos gastrointestinales
BR112012011485A2 (pt) "composições e métodos para tratar náusea e vômito centralmente mediados".
BR112016009954A2 (pt) terapia para o tratamento ou prevenção de condições associadas a sangramento hipocoagulação
BR112012006468A2 (pt) métodos de tratamento de inflamação
BRPI1011624A2 (pt) composição, métodos para reduzir um ou mais efeitos colaterais da terapia de glicocorticóide, e para tratar ou previnir um padrão de secreção de glicocorticóide endógeno diminuído ou interrompido em um paciente.
BR112014010542A2 (pt) métodos e composições para tratamento de ferimento
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
EA201200428A1 (ru) Композиция и способ для лечения ожирения
BR112012024887A2 (pt) grânulos de quitosana, preenchedor, processo para preparar os grânulos de quitosana, kit e disposto de injeção
BR112012029259A8 (pt) tratamento de infecção por clostridium difficile em pacientes sob terapia de antibióticos
BR112014027213A2 (pt) nova composição de alfentanil para o tratamento da dor aguda
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
BR112012028153A2 (pt) composição farmacêutica e método para o tratamento de hipertensão
BR112015023368A2 (pt) método de tratamento de deficiência de vitamina b12
BRPI0507302A (pt) método e composições para o tratamento da lipodistrofia
BR112014018709A8 (pt) Composições e efetores de beta-arrestina e métodos de uso dos mesmos
PH12014501044B1 (en) Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells
BR112012025703A2 (pt) métodos e composições para o tratamento de síndrome de intestino irritável

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]